Annual report pursuant to Section 13 and 15(d)

Income Taxes (Narrative) (Details)

v3.21.2
Income Taxes (Narrative) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Apr. 23, 2023
Jun. 10, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Expense (Benefit) [Line Items]          
Impairment of intangible assets     $ 14,100,000   $ 14,100,000
Corporate income tax rate       21.00% 21.00%
Income tax benefit       $ 3,129,138 $ 1,078,441
Unrecognized tax benefits     0 0 0
Penalties and interest expense       $ 0 $ 0
Tax Rate, Income tax expense (benefit) at U.S. federal statutory rates       21.00% 21.00%
Minimum [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards, expiration date       Dec. 31, 2022  
Maximum [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards, expiration date       Dec. 31, 2038  
Expiring 2040 [Member] | U.S. federal research and development tax credit carryforwards [Member]          
Income Tax Expense (Benefit) [Line Items]          
Tax credit carryforward       $ 2,800,000  
Tax Credit Carryforward, Expiration Date       Dec. 31, 2040  
Domestic [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       $ 39,100,000  
Domestic [Member] | 2022 to 2038 [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       30,500,000  
Domestic [Member] | Indefinite [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       8,600,000  
State [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       24,900,000  
State [Member] | 2022 to 2038 [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       22,500,000  
State [Member] | Indefinite [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       2,400,000  
Foreign [Member] | Indefinite [Member]          
Income Tax Expense (Benefit) [Line Items]          
Operating loss carryforwards       63,500,000  
United States [Member]          
Income Tax Expense (Benefit) [Line Items]          
Valuation allowance     11,700,000 16,400,000 $ 11,700,000
United States [Member] | Domestic [Member]          
Income Tax Expense (Benefit) [Line Items]          
Valuation allowance, deferred tax asset, change in amount       4,700,000  
U.K. [Member]          
Income Tax Expense (Benefit) [Line Items]          
Increase in deferred tax assets       3,700,000  
Valuation allowance, deferred tax asset, change in amount       700,000  
Income tax benefit       3,000,000.0  
U.K. [Member] | United Kingdom [Member]          
Income Tax Expense (Benefit) [Line Items]          
Corporate income tax rate   19.00%      
Tax Rate, Income tax expense (benefit) at U.S. federal statutory rates   19.00%      
U.K. [Member] | Scenario, Forecast [Member] | Enacted U.K. Tax Rate Increase [Member]          
Income Tax Expense (Benefit) [Line Items]          
Corporate income tax rate 25.00%        
Tax Rate, Income tax expense (benefit) at U.S. federal statutory rates 25.00%        
U.K. [Member] | The Female Health Company Limited [Member]          
Income Tax Expense (Benefit) [Line Items]          
Valuation allowance     2,400,000 3,200,000 2,400,000
Acquired In-Process Research and Development [Member]          
Income Tax Expense (Benefit) [Line Items]          
Intangible assets, net     $ 3,900,000 $ 3,900,000 $ 3,900,000